Advertisement

Topics

Companies Related to "IL-4(38-37)-PE38KDEL Immunotoxin in Treating Patients With Recurrent Malignant Astrocytoma" [Most Relevant Company Matches] RSS

08:44 EST 20th February 2019 | BioPortfolio

Here are the most relevant search results for "IL-4(38-37)-PE38KDEL Immunotoxin in Treating Patients With Recurrent Malignant Astrocytoma" found in our extensive corporate database of over 50,000 company records.

Showing "PE38KDEL Immunotoxin Treating Patients With Recurrent Malignant Astrocytoma" Companies 1–25 of 4,000+

Relevant

Genetronics Biomedical

Genetronics' most advanced effort involves treating those with head and neck cancer, a particularly devastating cancer that can severely limit the ability of these patients to see, taste, hear, talk, breathe, or swallow. Genetronics received approval from the U.S. Food and Drug Administration and initiated Phase II multi-center clinical trials at nine sites in the U.S. The trials test the effectiv...


Protox Therapeutics Inc.

Protox Therapeutics is a product-focused development-stage company and a leader in advancing novel, targeted protein toxin therapeutics for the treatment of cancer and other proliferative diseases. Through the company’s INxin™ and PORxin™ technology platforms, therapeutic candidates are generated by engineering the naturally occurring toxins, Pseudomonas exotoxin and proaerolysin. These drug...

GT Medical Technologies, Inc.

Driven to overcome the limitations of current treatments for recurrent brain tumors and raise the standard of care, a team of brain tumor specialists joined forces and formed GT Medical Technologies with a purpose to prevent disease progression and improve quality of life for patients with recurrent brain tumors. Extensive clinical expertise informed the d...


Targeted Diagnostics and Therapeutics

TDT has emerged as a leader in the development of innovative molecular diagnostics and therapeutics that can improve the quality of life of patients with colorectal cancer and gastrointestinal malignancies. Focused on innovative research and cutting edge technology, TDT has developed highly specific tests to detect colorectal cancer cells in lymph nodes from patients who have undergone surgical st...

OPi Ltd

Founded in 1999, OPi is a European integrated biopharmaceutical company whose mission is to develop and market pharmaceuticals (small molecules and biologicals) aimed at treating patients suffering from rare and severe diseases. OPi’s primary focus is onco-haematology, with a R&D portfolio of monoclonal antibodies at various stages of development, and with Kidrolase® (L-asparaginase) and Erwina...

Intrinsic Therapeutics, Inc.

Intrinsic Therapeutics is dedicated to treating soft-tissue injuries of the spine. Intrinsic's Barricaid anular reconstructive products are used during discectomy to definitively close defects in the posterior anulus. By restoring anular competence, the Barricaid family of products may reduce the risk of recurrent herniation while maintaining disc height and biomechanics.

US HIFU, LLC

US HIFU, LLC, a privately held healthcare company, is a world leader in minimally invasive high intensity focused ultrasound (HIFU) technologies. US HIFU manufactures the Sonablate® 500 medical device and is focused currently on treating primary and recurrent prostate cancer using Sonablate® HIFU. The company is engaged in ongoing research for technological advancements for the Sonablate® syste...

Targeted Diagnostics & Therapeutics, Inc

TDT has emerged as a leader in the development of innovative molecular diagnostics and therapeutics that can improve the quality of life of patients with colorectal cancer and gastrointestinal malignancies. Focused on innovative research and cutting edge technology, TDT has developed highly specific tests to detect colorectal cancer cells in lymph nodes from patients who have undergone surgical st...

USHIFU, LLC

USHIFU, LLC (US HIFU), a privately held healthcare company, is a world leader in minimally invasive high intensity focused ultrasound (HIFU) technologies. US HIFU manufactures the Sonablate® 500 medical device and is focused currently on treating primary and recurrent prostate cancer using Sonablate® HIFU. The company is engaged in ongoing research for technological advancements for the Sonablat...

Sensipar® (cinacalcet HCl)

Sensipar® (cinacalcet HCl) is an innovative, first-in-class, oral therapy indicated to treat hyperparathyroidism (excessive levels of parathyroid hormone) caused by chronic kidney disease; it is approved for use in patients who are receiving dialysis. It is also indicated to treat elevated calcium levels in patients with malignant tumors of the parathyroid gland.

Castle Biosciences Inc.

Castle Biosciences is a molecular diagnostics and prognostics company dedicated to helping patients and physicians make optimal decisions regarding treatment and follow-up care based on the tumor’s unique molecular signature. The Company currently offers prognostic tests for patients with rare cancers including uveal and cutaneous melanoma, esophageal...

NewLink Genetics Corporation

NewLink Genetics Corporation is a biopharmaceutical company developing novel drugs and functional genomics solutions with a primary focus on cancer.The successful completion of the Human Genome Project signals a new age in medical discovery centered on protein research. The rapidly growing knowledge base of the human genome provides an unprecedented opportunity to launch a revolutionary paradigm ...

Cellectar, Inc.

Cellectar, Inc. is a clinical stage radiopharmaceutical company that designs, develops and manufactures products to detect, treat and monitor a wide variety of human cancers. Cellectar's novel product candidates combine lipid-like molecules, phospholipid ethers (PLEs) analogs, with radioisotopes that can either image or destroy malignant cells. Cellectar's products' unique mechanism of action is ...

NeoMatrix, LLC

Based in Irvine, Calif., NeoMatrix© develops innovative devices that allow women and their doctors to promote optimal breast health. The company's premier product, the HALO Breast Pap Test System, is the first fully automated, noninvasive breast cancer risk assessment tool designed for use in the primary care office setting. The System has been FDA cleared for the collection of nipple aspirate fl...

NeuroPace, Inc.

NeuroPace was founded to design, develop, manufacture and market implantable devices for the treatment of neurological disorders by responsive brain stimulation. The company's initial focus is the treatment of epilepsy, a debilitating neurological disorder affecting approximately 1% of the population worldwide. Patients are currently being enrolled in a clinical trial of the company's Responsive N...

CerebralRx

Based in Yehud, Israel, CerebralRx was founded in 2010 as a spin-off of BioControl Medical to develop breakthrough implantable neuromodulation systems for the treatment of autonomic nervous system-related neurological disorders. The company’s flagship product is the FitNeS system, an implantable vagus nerve stimulation device for treating patients wit...

Finch Therapeutics Group, Inc.

Finch Therapeutics Group is developing novel microbial therapies to serve patients with serious unmet medical needs. Founded by data scientists, clinicians, and microbiologists from MIT and OpenBiome, Finch uses innovative machine-learning algorithms informed by high-throughput molecular data to reverse engineer successful clinical experience, building upo...

Ortho Biotech, L.P.

Ortho Biotech Products, L.P. is a leading biopharmaceutical company devoted to helping improve the lives of patients with cancer and with anemia due to multiple causes, including chronic kidney disease. Since it was founded in 1990, Ortho Biotech and its worldwide affiliates have earned a global reputation for researching, manufacturing and marketing innovative products that enhance patients'...

Rebiotix Inc.

Rebiotix Inc, which is part of the Ferring Pharmaceuticals Group, is a late-stage clinical microbiome company focused on harnessing the power of the human microbiome to revolutionize the treatment of debilitating diseases. Rebiotix possesses a deep and diverse clinical pipeline, with its lead drug candidate, RBX2660, in Phase 3 clinical development for th...

Ortho Biotech Products, L.P.

Ortho Biotech Products, L.P. is a leading biopharmaceutical company devoted to helping improve the lives of patients with cancer and with anemia due to multiple causes, including chronic kidney disease. Since it was founded in 1990, Ortho Biotech and its worldwide affiliates have earned a global reputation for researching, manufacturing and marketing innovative products that enhance patients'...

Gamma Knife Centre

Gamma Knife Surgery is a non-invasive method used for the treatment of arteriovenous malformations (AVMs), benign and malignant tumours of the brain. It does not involve traditional surgical incisions and thus devoid of post-operative complications with virtually no risk of mortality. There is no lengthy recuperation and most patients return to work within 2 to 3 days

Global Coalition for Adaptive Research

The Global Coalition for Adaptive Research (GCAR) is a 501(c)(3) non-profit charitable organization, comprised of some of the world’s foremost physicians, clinical researchers and investigators united in expediting the discovery and development of cures for patients with rare and deadly diseases. As its first priority, GCAR is sponsoring GBM AGILE, an...

ADD dental facility

Dr Nick Mohindra first became interested in this field when he was treating patients who were suffering from what is known as TMD syndrome. This is a group of symptoms including sore facial muscles, tense neck and shoulders, or back and head pains, often caused by jaw relationship problems. It occurred to him that the technique he was using to treat these patients could also benefit denture patien...

Sinexus, Inc.

Sinexus, Inc. (http://www.sinexusinc.com) is a development-stage medical device company that is pioneering novel therapies for Ear, Nose & Throat (ENT) physicians to utilize in providing improved treatment for their patients. Sinexus' initial focus is treating patients with Chronic Rhinosinusitis, a debilitating chronic condition that affects one out of seven adults in the United States.

Pharmablood

PharmaBlood performs R&D of personalized medical treatment methods using as therapeutic agents autologous blood derivative compositions in cancer patients.PharmaBlood is a trademark of Telemedical Organization Inc used to identify the activity of the company in the field of research and development of blood derivatives as medical therapeuticals.Telemedical Organization Inc is an American company w...


More From BioPortfolio on "IL-4(38-37)-PE38KDEL Immunotoxin in Treating Patients With Recurrent Malignant Astrocytoma"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks